A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease by Severi, G et al.
ORIGINAL RESEARCH
A three-protein biomarker panel assessed in diagnostic
tissue predicts death from prostate cancer for men with
localized disease
Gianluca Severi1,2, Liesel M. FitzGerald1,*, David C. Muller1,2,*, John Pedersen1,3,4,*, Anthony Longano4,
Melissa C. Southey1,5, John L. Hopper1,2, Dallas R. English1,2, Graham G. Giles1,2,* & John Mills3,4,6,*
1Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria 3004, Australia
2Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne,
Victoria 3010, Australia
3TissuPath Specialist Pathology, Mount Waverley, Victoria 3149, Australia
4Faculty of Medicine, Monash University, Victoria 3800, Australia
5Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia
6Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria 3004, Australia
Keywords
AZGP1, immunohistochemistry, MUC1,
NKX3.1, p53, prognostic markers, prostate
cancer-specific death
Correspondence
John Mills, Monash University Faculty of
Medicine, Central Clinical School, Melbourne,
Victoria 3004, Australia.
Tel: +61 419 877 472; Fax: +61 3 804 8124;
E-mail: john.mills@monash.edu
Funding Information
Recruitment and follow-up of men
participating in the Cancer Council Victoria
Prostate Cancer Program was funded by
Cancer Council Victoria, VicHealth, Tattersalls,
the E. J. Whitten Foundation, and the Prostate
Cancer Foundation of Australia. Dr FitzGerald
is the Cancer Council Victoria David Hill Fellow
and is funded by a Movember and Cure
Cancer Australia Foundation Young
Investigator Grant awarded through Prostate
Cancer Foundation of Australia’s Research
Program. Further support for this study was
provided by the Australian National Health and
Medical Research Council (project grant
#504700) and by a grant from TissuPath
Research Pty Ltd. (a subsidiary of TissuPath
Specialist Pathology).
Received: 24 March 2014; Revised: 6 May
2014; Accepted: 7 May 2014
Cancer Medicine 2014; 3(5): 1266–1274
doi: 10.1002/cam4.281
*These authors contributed equally to the
article.
Abstract
Only a minority of prostate cancers lead to death. Because no tissue biomarkers
of aggressiveness other than Gleason score are available at diagnosis, many non-
lethal cancers are treated aggressively. We evaluated whether a panel of biomar-
kers, associated with a range of disease outcomes in previous studies, could
predict death from prostate cancer for men with localized disease. Using a case-
only design, subjects were identified from three Australian epidemiological
studies. Men who had died of their disease, “cases” (N = 83), were matched to
“referents” (N = 232), those who had not died of prostate cancer, using inci-
dence density sampling. Diagnostic tissue was retrieved to assess expression of
AZGP1, MUC1, NKX3.1, p53, and PTEN by semiquantitative immunohisto-
chemistry (IHC). Poisson regression was used to estimate mortality rate ratios
(MRRs) adjusted for age, Gleason score, and stage and to estimate survival
probabilities. Expression of MUC1 and p53 was associated with increased mor-
tality (MRR 2.51, 95% CI 1.14–5.54, P = 0.02 and 3.08, 95% CI 1.41–6.95,
P = 0.005, respectively), whereas AZGP1 expression was associated with
decreased mortality (MRR 0.44, 95% CI 0.20–0.96, P = 0.04). Analyzing all
markers under a combined model indicated that the three markers were inde-
pendent predictors of prostate cancer death and survival. For men with local-
ized disease at diagnosis, assessment of AZGP1, MUC1, and p53 expression in
diagnostic tissue by IHC could potentially improve estimates of risk of dying
from prostate cancer based only on Gleason score and clinical stage.
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Introduction
In developed countries, prostate cancer (PCa) is the most
common noncutaneous cancer in males, but with the wide-
spread use of prostate-specific antigen (PSA) testing and
prostate biopsies, the majority of prostate tumors now
diagnosed are localized (i.e., confined within the prostate
gland), slow growing, and unlikely to metastasise [1].
Despite this, and the fact that 5-year survival is generally
higher than 85% [2, 3], a large number of patients still opt
for surgery (radical prostatectomy) due to a reduction in
disease-specific mortality, especially in men younger than
65 years [4], or radiotherapy. One of the major factors
driving the choice for invasive therapy is that although sev-
eral prognostic algorithms have been developed based on
the clinical features of a tumor, the ability of these models
to predict disease outcome, and specifically prostate can-
cer-specific mortality (PCSM), is still quite limited [5–9].
To more accurately predict which tumors are likely to
remain indolent and which will progress, additional prog-
nostic variables, such as tissue biomarkers, need to be iden-
tified and incorporated into current algorithms.
Numerous immunohistochemistry (IHC) studies have
examined the prognostic value of biomarkers in PCa tumor
tissue. While the majority of studies have involved small
numbers of samples resulting in detected associations not
holding up to multivariable analysis, recently there have
been some promising results from a few larger, more robust
studies. In an IHC analysis of tissue from 5718 radical pro-
statectomy specimens, Tsourlakis et al. found expression of
the death-domain-associated protein (DAXX) to be inde-
pendently associated with biochemical recurrence and to be
a potential independent prognosticator of PCa outcomes
[10]. In two other large studies of 1826 and 7964 radical
prostatectomy specimens, the NF-jB and KPNA2 proteins
were also found to be associated with biochemical recur-
rence, independently of clinical prognostic factors [11, 12].
As disease prognosis and treatment decisions are the
principal challenges for those patients with clinically
localized disease at diagnosis [13, 14], it is important to
identify biomarkers that are prognostic for disease out-
comes in this specific group of patients. Studying this
demographic of patients, however, is in itself challenging
due to the rarity of diagnostic specimen collections with
outcomes data such as metastasis and PCSM. Despite
these challenges, promising diagnostic biomarkers have
been identified. The p16 protein was observed to be inde-
pendently associated with PCSM in a multivariate analysis
of tissue microarrays containing clinically localized trans-
urethral resection of the prostate (TURP) specimens [15],
while loss of PTEN expression in localized diagnostic
specimens was significantly associated with PCSM in uni-
variate analyses [16]. Interestingly, in this latter study the
association only remained significant in multivariate
analyses of patients diagnosed with clinically low-risk dis-
ease and not with clinically high-risk disease. In a study
of locally advanced PCa cases, p53 was observed to be
significantly associated with metastasis and PCSM [17];
while in a more recent, independent study of clinically
localized PCa cases, Kudahetti et al. also observed an
association of p53 expression with PCSM [18].
Despite these promising results, few biomarkers have
been tested and validated in diagnostic tissue from localized
tumors and no biomarkers have yet been established for
widespread clinical usage. The aim of this study was to
assess expression of a panel of tissue biomarkers including
AZGP, MUC1, p53, NKX3.1, and PTEN using IHC on
archival tissue collected at the time of diagnosis and to
determine whether expression of these biomarkers predicts
PCSM independently of Gleason score and clinical stage.
Materials and Methods
Sample selection
Study participants were men diagnosed with histologically
confirmed PCa recruited into three epidemiological stud-
ies run by the Prostate Cancer Research Program of the
Cancer Council Victoria. These studies include 964 men
from the Melbourne Collaborative Cohort Study (MCCS),
786 men from the Melbourne arm of the Risk Factors for
Prostate Cancer case–control study (RFPCS), and 1230
men from the Early-Onset Prostate Cancer Family Study
(EOPCFS). The MCCS series included all men diagnosed
with PCa during follow-up of a cohort of 41,514 volun-
teers (17,045 men) recruited in Melbourne during 1990–
1994 [19, 20]. For this study, follow-up ended on the 1
January 2005, which was the latest date for which com-
plete cause of death information was available at the time
of sample selection. The RFPCS is a population-based,
case–control study that between 1994 and 1997 recruited
men resident in Sydney, Perth, and Melbourne diagnosed
with PCa at age <70 years [21, 22]. Eligible men with
PCa were ascertained through Australian state Cancer
Registries and had to be histologically confirmed with a
Gleason score higher than 4. The EOPCFS is a popula-
tion-based study with the principal aim of identifying
genetic risk factors for early-onset PCa [23]; men were
recruited who had been diagnosed with PCa before age
60 years and who were reported to the Victorian Cancer
Registry between 2000 and 2009. Participants in these
three studies were followed passively from date of PCa
diagnosis via linkage to the Victorian Registry of Births,
Deaths, and Marriages (VRBDM), and the National Death
Index (NDI), both of which obtain cause of death data
from the Australian Bureau of Statistics.
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In 2007, we began a nested case–referent study within
the MCCS, RFPCS, and EOPCFS to identify factors associ-
ated with PCSM. Cases were defined as those men diag-
nosed with localized disease (T1–T3b) and whose death
was ascribed to PCa by the Australian Bureau of Statistics
(cause of death codes C61 or 185) between diagnosis and 1
January 2005 for MCCS participants, or 1 January 2007 for
RFPCS and EOPCFS participants. Cause of death was
reviewed by an expert coder and PCSM was confirmed for
213 men (hereafter referred as “cases”). For each case, we
then randomly selected two men (hereafter referred to as
“referents”) using risk set (i.e., density) sampling with years
since diagnosis as the time scale. Thus, to be eligible as a
referent, each man had to have survived at least as long as
the corresponding case. Cases and referents were matched
for Gleason score at diagnosis as recorded by the Victorian
Cancer Registry (<7, 7 [3+4], 7 [4+3], 8–10, or unknown).
This study was approved by the Human Research and
Ethics Committee of the Cancer Council Victoria.
Immunohistochemical staining
Three micron tissue sections were taken from selected
blocks following review and stored at 4°C in desiccated
containers until used. IHC was performed using the Leica
Bond-Max autostainer (Leica Microsystems Pty Ltd,
North Ryde, NSW, Australia). All primary antibody incu-
bations were for 30 min. The detection system used was
the Novocastra Novolink Max polymer (RE7320-K; Leica
Microsystems Pty Ltd) with the DAKO DAB chromogen
(Dako Australia Pty. Ltd., North Sydney, NSW, Austra-
lia). The antibodies used were the following: Novocastra
NCL-PTEN HIER citrate 1/400 (PTEN), Novocastra
NCL-MUC-1 HIER citrate 1/400 (MUC1), Novocastra-
P53-D07 HIER 1/300 (p53), Zymed 35-9700 HIER citrate
1/250 (NKX3.1; Life Technologies Australia Pty Ltd, Mul-
grave, Vic., Australia), and Santa Cruz SC-11358 (AZGP1
or ZAG H-123; ThermoFisher Scientific, Scoresby, Vic.,
Australia). Level of staining was assessed by one of the
authors (J. P.), an anatomical pathologist specializing in
urological cancers, who was masked to the status of the
participant (i.e., case or referent). For each case the tissue
block corresponding with the highest Gleason score was
selected, sections were cut, and the resulting slides were
stained for the five biomarkers by IHC. Biomarker expres-
sion was recorded as both the proportion of stained
tumor cells (0–100%) and overall staining intensity
(none, weak, moderate, or strong, i.e., 0–3+). If different
Gleason patterns were present on the same slide, expres-
sion was recorded for each of them. If multiple areas with
the same Gleason pattern were present on the slide,
expression was averaged across them. For MUC1, AZGP1,
and PTEN staining was only present in the cytoplasm
while for p53 it was present only in the nucleus. For
NKX3.1 we considered only cytoplasmic staining as posi-
tive as nuclear staining was ubiquitous. The data used for
this study were binary, including only the proportion of
stained tumor cells for the highest Gleason pattern cate-
gorized by either not expressed (<5% staining) versus
expressed (≥5% staining).
Reproducibility of the IHC scoring was assessed using
20 slides for each marker which were independently
assessed by another pathologist (A. L.) masked to J. P.’s
results. Slides for this study were selected at random and
in a way to ensure an equal distribution of expression
and nonexpression of each biomarker.
Statistical analysis
Mortality rate ratios (MRR) and 95% confidence intervals
(CI) for IHC biomarker expression were estimated using
Poisson regression models with PCSM as the outcome
[24]. For cases, duration of follow-up was calculated as
the time from diagnosis to death from PCa. For referents,
it was set to the value of their corresponding matched
case. Restricted cubic splines with three knots (placed at
the 25th, 50th, and 75th percentiles of observed log fol-
low-up time) were used to model the baseline mortality
rate. In order to account for the sampling scheme, the
Poisson likelihood was weighted for each observation by
the inverse probability of inclusion in the sample. Each
case, therefore, had an inverse probability of inclusion of
1, and each referent had an inverse probability weight
equal to half the size of the risk set from which it was
sampled. This weighting scheme thus recovers the com-
plete person-time experience of all cases eligible to be
included in the case–referent study, and yields a Poisson
pseudo-likelihood analogous to that of the parametric
survival models described by Kalbfleisch and Lawless [24].
We fitted separate models for each of AZGP1, MUC1,
p53, PTEN, and NKX 3.1, as well as a combined model
including all markers associated with PCSM. We esti-
mated marginal 5-year survival probabilities using the
Kaplan–Meier method for all cases and separately by
Gleason score. Predicted marginal 5-year survival proba-
bilities were calculated from the combined model for
every combination of marker expression. Confidence
intervals for the predicted survival function S(t) were cal-
culated using the delta method estimate of the variance of
log(log(S(t))) back transformed to the natural metric.
All models were adjusted for tumor stage, Gleason score
(<7, 7 [3+4], 7 [4+3], 8–10), and age at diagnosis. The
Wald test was used to compute P-values for coefficients.
In secondary analyses, we restricted the models to cases
and referents that had been treated by radical prostatecto-
my. For sensitivity analyses, we fitted conditional logistic
1268 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Tissue Biomarkers and Prostate Cancer Mortality G. Severi et al.
regression for the complete case–referent sets (i.e., sets
including one case and at least one referent) to compare
the odds ratios with the MRR obtained from the Poisson
models (unconditional analysis). For the analyses con-
ducted to determine whether the scoring of the staining
was reproducible, we calculated separately for each mar-
ker the proportion of slides that were scored consistently
by the two pathologists and estimated the Cohen’s kappa
statistics using expression in two categories (expressed vs.
not expressed) as for the other analyses.
All statistical analyses were performed using Stata 12.1
for Linux 64-bit (Stata Corporation, College Station, TX).
Results
Due to financial limitations, the present study was
restricted to a randomly selected subset of 102 cases and
254 referents for whom we attempted to retrieve diagnos-
tic archival tissue. In most instances diagnostic tissue was
in the form of “cores” obtained by a trans-rectal, ultra-
sound-guided (TRUS) needle biopsy, in the others it was
in the form of “chips” obtained by a TURP. Diagnostic
tissue specimens were not able to be retrieved for 19 cases
and 22 referents, leaving a total of 83 cases and 232 refer-
ents available for analysis. This sample of cases and refer-
ents was similar to the remaining 283 cases and referents
for whom we did not attempt tissue collection in terms
of age at diagnosis (median 64, range 41–77 years and 65,
39–79 years, respectively) and time to death (median 4.5,
range 0.1–11.1 years and 5.5, 1.4–9.0 years, respectively).
The distribution of Gleason score did not differ dramati-
cally between the two groups: of those not included in
this study, 30% had Gleason score less than 7, 30% had
Gleason score of 7, and 40% had Gleason score of 8–10
while the proportions were 18%, 42%, and 42%, respec-
tively for those included in this study.
The main clinical characteristics of subjects in this
study are shown in Table 1. For cases, the median time
between diagnosis and PCSM was 4.4 years (interquartile
range 2.8–6.4 years). Analysis of the individual protein
expression data revealed that those men with diagnostic
tissue expressing AZGP1 had a 56% lower rate of PCSM
than those with biopsies not expressing this biomarker,
while expression of MUC1 or p53 was associated with a
substantially increased rate of PCSM (Table 2). Associa-
tions remained remarkably strong in a combined model
that included AZGP1, MUC1, and p53. Adjusting for sub-
sequent radical prostatectomy did not materially change
the estimates from the combined Poisson model, with
MRRs (95% CIs) of 0.48 (0.20–1.16), 2.44 (1.03–5.75),
and 3.04 (1.31–7.09) for AZGP1, MUC1, and p53, respec-
tively. Further adjustment of the models by year of diag-
nosis also did not materially change the estimated MRRs.
As a sensitivity analysis we also fitted a combined con-
ditional logistic regression model using data from the 57
matched case–referent sets with at least one matched ref-
erent (i.e., a total of 57 cases and 89 referents). These
results were broadly consistent with those of the com-
bined Poisson model, with odds ratios (95% CIs) of 0.58
(0.25–1.35), 2.68 (0.94–7.59), and 1.96 (0.80–4.82) for
AZGP1, MUC1, and p53 expression, respectively. A sensi-
tivity analysis including only TRUS samples also provided
similar results, with MRRs (95% CIs) of 0.35 (0.12–1.01),
1.79 (0.61–5.28), and 3.10 (1.24–7.74) for AZGP1,
MUC1, and p53, respectively.
We found no evidence of statistical interaction between
any of the assessed markers (data not shown) and, there-
fore, calculated predicted marginal survival probabilities
for given marker expression patterns directly from the
combined Poisson model including AZGP1, MUC1, and
p53. In our study the overall 5-year survival probability for
men with PCa was 97% (99% for Gleason score 6 prostate
cancer). The predicted 5-year disease-specific survival
probabilities for a man diagnosed at the median diagnosis
age (63 years), with a Gleason score 8–10 and a clinical
stage T1c tumor are shown in Figure 1 for each combina-
tion of marker expression. We observed substantial varia-
tion in the 5-year survival probabilities across different
Table 1. Personal and tumor characteristics of cases and referents.
Referents
(N = 232)1
Cases
(N = 83)2
Total
(N = 315)
Diagnosis age, years,
median (interquartile
range)
63 (57–68) 64 (58–68) 63 (58–68)
Time to death, years,
median (interquartile
range)
4.4 (2.8–6.4)
Diagnosis year, N (%)
1992–1995 88 (38) 35 (42) 123 (39)
1996–2000 121 (52) 40 (48) 161 (51)
2001–2005 23 (10) 8 (10) 31 (10)
Gleason score3, N (%)
<7 53 (25) 8 (11) 61 (21)
7 (3 + 4) 45 (21) 20 (26) 65 (23)
7 (4 + 3) 28 (13) 15 (20) 43 (15)
8–10 86 (41) 33 (43) 119 (41)
Clinical stage4, N (%)
1A, 1B 60 (26) 25 (30) 85 (27)
1C 118 (52) 56 (67) 174 (56)
2B, 3A, or 3B 49 (22) 2 (2) 51 (16)
1Referents were men with prostate cancer who were at risk of PCSM
at the time of death of their corresponding case.
2Cases were men who died during the follow-up period whose death
was attributed to prostate cancer.
3Gleason score was not available for 27 men (7 cases and 20
referents).
4Clinical stage was unavailable for five referents.
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marker expression categories ranging from 0.90 (95% CI
0.61–0.97) for tumors expressing only AZGP1 to 0.36 (95%
CI 0.05–0.71) for tumors expressing MUC1 and p53 but
not AZGP1. For men with Gleason score 6 and clinical
stage T1c tumors, 5-year survival probability was higher
than 0.98 for tumors expressing AZGP1 only or AZGP1
and MUC-1, while it was 0.86 (95% CI 0.54–0.97) for
tumors expressing MUC1 and p53 but not AZGP1 (Fig. 2).
The agreement in the IHC scoring of the tissue specimens
between the two independent pathologists was very good
for AZGP1, MUC1, p53, and PTEN with 89%, 84%, 95%,
and 100% of the slides, respectively, being concordant and
the j-statistics being 0.76, 0.69, 0.89, and 1, respectively.
For NKX3.1, the agreement was slightly lower with 78%
concordant and j statistics equal to 0.49.
Discussion
Our study shows that semiquantitative IHC assessment of
the expression of three proteins in diagnostic tissue,
AZGP1, MUC1, and p53, taken together as a biomarker
panel, predicts risk of PCSM beyond the risk predicted by
Table 2. Cause-specific mortality in relation to biomarker expression1.
N referents
(% expressing)2
N cases
(% expressing)3 MRR 95% CI P
Individual marker models4
AZGP1 expression 219 (42%) 81 (32%) 0.44 (0.20, 0.96) 0.04
MUC1 expression 224 (64%) 82 (82%) 2.51 (1.14, 5.54) 0.02
NKX 3.1 expression 200 (70%) 78 (72%) 1.15 (0.42, 3.17) 0.79
p53 expression 219 (57%) 82 (76%) 3.08 (1.41, 6.95) 0.005
PTEN expression 221 (96%) 81 (96%) 1.11 (0.18, 6.95) 0.91
Combined model4
AZGP1 expression 218 (43%) 81 (32%) 0.47 (0.20, 1.08) 0.08
MUC1 expression 218 (63%) 81 (81%) 2.10 (0.94, 4.69) 0.07
p53 expression 218 (56%) 81 (75%) 2.76 (1.23, 6.20) 0.01
1MRR, mortality rate ratio estimated from Poisson regression models with prostate cancer-specific death as the outcome; CI, confidence interval.
2Referents were men with prostate cancer who were at risk of prostate cancer-specific mortality at the time of death of their corresponding case.
3Cases were men who died during the follow-up period whose death was attributed to prostate cancer.
4Models were adjusted for age at diagnosis, stage, Gleason score, and study. Slides marked as inappropriate for data analysis by the pathologist
(J. P.) were excluded. For the “individual marker models,” five different models were fitted each with only one marker included. For the
“combined model,” a single model was fitted including all the three markers that had a “statistically significant” MRR from the individual marker
models.
MUC1 and p53 (42% cases, 24% controls)
AZGP1, MUC1, and p53 (20% cases, 16% controls)
p53 only (11% cases, 11% controls)
MUC1 only (11% cases, 11% controls)
AZGP1 and p53 (2% cases, 5% controls)
AZGP1 and MUC1 (9% cases, 14% controls)
No markers expressed (4% cases, 12% controls)
AZGP1 only (1% cases, 8% controls)
Bi
om
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r 
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n
0.2 0.4 0.6 0.8 0.9 0.95 0.99
5−year survival probability (log−log scale)
Figure 1. Predicted 5-year survival probabilities and 95% confidence intervals for given biomarker expression patterns. Predictions are based on
the median age at diagnosis (63 years) and the most common Gleason score and clinical stage in the sample of cases (8–10 and 1c, respectively).
Overall, the 5-year survival probability was 0.98 (95% CI: 0.97–0.98), and 0.84 (95% CI: 0.75–0.90) for Gleason score 8–10 prostate cancer.
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“conventional” variables such as Gleason pattern and
stage. Expression of AZGP1 alone was associated with a
threefold decreased risk of PCSM compared with nonex-
pression, while MUC1 or p53 expression was associated
with a twofold increased risk compared with nonexpres-
sion. Most importantly, a combined assessment of these
three markers suggests that they are independent predic-
tors of PCSM and can discriminate between cases at high
risk from those at low risk of dying from PCa.
The expression of p53 protein has previously been
shown to be associated with PCSM in diagnostic tumor
specimens [17, 18]. In a series of 777 biopsy specimens
from locally advanced PCa cases, Che et al. found p53 to
be significantly associated with metastasis and PCSM in
both univariate and multivariate analyses [17]. Interest-
ingly, when cases were stratified by treatment type, the
association with PCSM only remained significant in those
patients who received short-term androgen deprivation
therapy with radiation therapy and not in patients who
received long-term androgen deprivation therapy with
radiation therapy. While our study did not have full treat-
ment data available for stratified analyses, adjusting for
subsequent radical prostatectomy did not materially
change the association between p53 expression and
PCSM. In second independent study of 705 TURP speci-
mens comprising clinically localized cases, Kudahetti et al.
also observed a significant association between p53
expression and PCSM [18]. When cases were stratified
according to Gleason score, the association only remained
significant in cases with Gleason scores 8–10. We
observed the expected variation in 5-year survival
probabilities when looking at marker expression in differ-
ent Gleason score categories. A low survival probability
was observed in Gleason score 8–10 patients expressing
p53 and MUC1, but not AZGP1 (0.36), whereas a higher
survival probability was observed in Gleason score 6
(0.86) patients.
AZGP1 and MUC1 were first identified as candidate
markers of PCa aggressiveness by a study that used cDNA
microarrays to compare gene expression in fresh-frozen
radical prostatectomy specimens, fresh-frozen “normal”
prostate tissue from these same surgical specimens, and
lymph node metastases [25]. These findings were then
confirmed using semiquantitative IHC on tissue micro-
arrays of independent radical prostatectomy tumor speci-
mens, using biochemical recurrence as outcome. MUC1
expression was shown to be higher in tumor than in nor-
mal tissue, and one study found that expression was high-
est in Gleason score 8–10 tumors and in lymph node
metastases, although these observations were limited to a
small sample [26]. Another study showed that MUC1
expression correlated with increased microvessel density, a
feature that is common in high-grade tumors [27]. For
AZGP1 the initial findings of Lapointe et al. were con-
firmed in a study using IHC on tissue from radical pro-
statectomy specimens, with clinical recurrence (i.e.,
localized recurrence, metastasis, or PCSM) as the out-
come [28]. Overall these studies provided strong evidence
that expression of MUC1 and absent or weak expression
of AZGP1 in radical prostatectomy specimens or tissue
microarrays were associated with worse disease outcomes.
Our study extends these findings and shows that expres-
sion of these two markers in diagnostic tissue is associ-
ated with PCSM that they are independent of other
MUC1 and p53 (42% cases, 24% controls)
AZGP1, MUC1, and p53 (20% cases, 16% controls)
p53 only (11% cases, 11% controls)
MUC1 only (11% cases, 11% controls)
AZGP1 and p53 (2% cases, 5% controls)
AZGP1 and MUC1 (9% cases, 14% controls)
No markers expressed (4% cases, 12% controls)
AZGP1 only (1% cases, 8% controls)
Bi
om
ar
ke
r 
ex
pr
es
sio
n
0.2 0.4 0.6 0.8 0.9 0.95 0.99
5−year survival probability (log−log scale)
Figure 2. Predicted 5-year survival probabilities and 95% confidence intervals for given biomarker expression patterns. Predictions are based on
the median age at diagnosis (63 years), Gleason score 6, and clinical stage 1c. Overall, the 5-year survival probability was 0.98 (95% CI: 0.97–
0.98), and 0.99 (95% CI: 0.98–1.00) for Gleason score 6 prostate cancer.
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established predictors of disease outcome, and together
with p53, allow good discrimination between men at low
and high risk of PCSM.
Deletions of the tumor suppressor gene PTEN and of
the transcription factor NKX3.1 are common in PCa but
evidence that expression of these proteins is associated
with prognosis is limited and inconclusive [16, 29–32]. A
recent study looking at PTEN expression in 675 TURP
specimens from clinically localized tumors observed that
loss of PTEN expression was highly predictive of PCSM
in low-risk patients (low Gleason score, low PSA, low
Ki-67, or low extent of disease) but not in high-risk
patients [16]. Our study does not support the hypothesis
that assessing the expression of these PTEN and NKX3.1
using IHC analysis on diagnostic tissue is useful for
predicting disease outcome. However, it must be noted
that our data are not the last word on PTEN as the MRR
confidence interval for this biomarker was very wide due
to ubiquitous expression in cases and referents and
further investigation of this protein is warranted.
Our study has several major strengths (1) the relatively
large number of cases that died from PCa and therefore,
the ability to use PCSM as the outcome; (2) the simulta-
neous evaluation and assessment of multiple biomarkers;
(3) limiting the analysis to patients with localized PCa;
(4) assessing formalin-fixed, paraffin-embedded diagnostic
tissue, thereby expanding the data to all patients with
prostate cancer, not just those who have had radical pros-
tatectomies or those where fresh-frozen tissue is available;
(5) assessment of all biomarkers by a single, masked,
expert uropathologist, and review by another, general
pathologist showing that these markers could be assessed
consistently; and (6) our results can be rapidly translated
into practice due to the use of standard prostate diagnos-
tic tissue (formalin-fixed and paraffin-embedded) and
IHC procedures using commercially available antibodies.
We selected IHC to assess protein expression as it is used
by virtually all pathologists, including those in middle- or
low-income countries and because it is simple and inex-
pensive (and where applicable, already reimbursed by
government and private insurers).
Despite the many strengths mentioned above, our
study does have some limitations. First, serum PSA con-
centrations at diagnosis were not available for our
patients, although this omission is unlikely to have con-
founded the observed associations. PSA at diagnosis is a
strong predictor of biochemical relapse [6] but not of
PCSM, of which the strongest predictor is Gleason score
[7]. Another potential limitation is that radical prostatec-
tomy was the only treatment information available and
previous studies have noted that biomarker prognostica-
tion does vary between treatment groups [17]. However,
it should be noted that the associations between marker
expression and PCSM were virtually unchanged when
estimated for the subset of surgically treated patients, sug-
gesting that treatment may not materially influence our
results. The matching of cases and referents was based on
Gleason scores from the original diagnostic histopathol-
ogy reports, and these same Gleason scores were used in
our analyses. It is possible that the grading of prostate
tumors has changed over the recruitment period of the
three studies (1990–2009), but as this would affect both
cases and referents equally it is unlikely to have influ-
enced our estimates of association. This assertion is cor-
roborated by the fact that adjustment for year at
diagnosis did not materially change the MRRs (data not
shown). The strong similarity between the MRRs from
the Poisson models and the odds ratios from the condi-
tional logistic regression indicates that the choice of Glea-
son score categories has a minimal impact, if any, on the
association between expression of the tissue biomarkers
and risk of PCSM. Finally, while our p53 results validate
those of two previous studies, and together provide com-
pelling evidence for the use of this biomarker in prognos-
tication, a validation dataset was not available for our full
panel of biomarkers and therefore these results need to be
confirmed in an independent case series.
In summary, our results, if validated in an independent
set of cases, show that a panel of markers, including
AZGP1, MUC1, and p53, could be assessed using routine
IHC at the time of diagnosis of clinically localized PCa.
This panel may help clinicians and patients make more
informed decisions around treatment options and there-
fore decrease unnecessary treatment for men at low risk
of dying from the disease and improve our ability to iden-
tify men that might benefit from aggressive treatment.
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